The need for an individual approach to lung cancer treatment.
作者信息
Shigematsu Hisayuki, Toyooka Shinichi, Suzuki Makoto
出版信息
PLoS Med. 2006 Apr;3(4):e206. doi: 10.1371/journal.pmed.0030206. Epub 2006 Apr 25.
Abstract
摘要
相似文献
1
The need for an individual approach to lung cancer treatment.肺癌治疗需要个体化方法。
PLoS Med. 2006 Apr;3(4):e206. doi: 10.1371/journal.pmed.0030206. Epub 2006 Apr 25.
2
Mutations in the epidermal growth factor receptor tyrosine kinase may predict response to gefitinib in non-small-cell lung cancer.表皮生长因子受体酪氨酸激酶的突变可能预测非小细胞肺癌对吉非替尼的反应。
Clin Lung Cancer. 2004 May;5(6):331-2. doi: 10.1016/s1525-7304(11)70182-6.
3
Epidermal growth factor receptor pathway inhibitors.表皮生长因子受体通路抑制剂
Cancer Chemother Biol Response Modif. 2005;22:205-23. doi: 10.1016/s0921-4410(04)22009-9.
4
ERBB2 kinase mutations in lung-cancer tumours.肺癌肿瘤中的ERBB2激酶突变。
Lancet Oncol. 2004 Nov;5(11):647. doi: 10.1016/s1470-2045(04)01626-2.
5
[Tumor response to gefitinib (IRESSA) in pulmonary adenocarcinoma: toward a molecular basis for therapeutic targetting].[吉非替尼（易瑞沙）对肺腺癌的肿瘤反应：迈向治疗靶点的分子基础]
Rev Mal Respir. 2004 Nov;21(5 Pt 1):881-5. doi: 10.1016/s0761-8425(04)71466-7.
6
Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis.表皮生长因子受体（EGFR）特定突变与临床特征对 EGFR 突变型肺癌患者接受 EGFR 酪氨酸激酶抑制剂与化疗治疗后结局的影响：一项荟萃分析。
J Clin Oncol. 2015 Jun 10;33(17):1958-65. doi: 10.1200/JCO.2014.58.1736. Epub 2015 Apr 20.
7
Role of tyrosine kinase inhibitors in lung cancer.酪氨酸激酶抑制剂在肺癌中的作用。
Anticancer Agents Med Chem. 2009 Jun;9(5):569-75. doi: 10.2174/187152009788451879.
8
[Targeted therapies for lung cancer].[肺癌的靶向治疗]
Rinsho Ketsueki. 2008 Aug;49(8):616-21.
9
Clinical development of gefitinib in non-small-cell lung cancer and the Iressa Survival Evaluation in Lung Cancer trial.吉非替尼在非小细胞肺癌中的临床开发及肺癌易瑞沙生存评估试验
Clin Lung Cancer. 2005 Jan;6(4):214-6. doi: 10.1016/s1525-7304(11)70473-9.
10
Variability in organ-specific EGFR mutational spectra in tumour epithelium and stroma may be the biological basis for differential responses to tyrosine kinase inhibitors.肿瘤上皮和基质中器官特异性表皮生长因子受体（EGFR）突变谱的变异性可能是对酪氨酸激酶抑制剂产生不同反应的生物学基础。
Br J Cancer. 2005 May 23;92(10):1922-6. doi: 10.1038/sj.bjc.6602557.
本文引用的文献
1
Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.由抑制剂敏感和耐药的表皮生长因子受体（EGFR）突变体引起的致癌转化
PLoS Med. 2005 Nov;2(11):e313. doi: 10.1371/journal.pmed.0020313. Epub 2005 Oct 4.
2
Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.肺腺癌中HER2激酶结构域的体细胞突变。
Cancer Res. 2005 Mar 1;65(5):1642-6. doi: 10.1158/0008-5472.CAN-04-4235.
3
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.肺腺癌对吉非替尼或厄洛替尼获得性耐药与表皮生长因子受体（EGFR）激酶结构域的二次突变有关。
PLoS Med. 2005 Mar;2(3):e73. doi: 10.1371/journal.pmed.0020073. Epub 2005 Feb 22.
4
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.表皮生长因子受体（EGFR）突变与非小细胞肺癌对吉非替尼的耐药性
N Engl J Med. 2005 Feb 24;352(8):786-92. doi: 10.1056/NEJMoa044238.
5
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.肺癌中的表皮生长因子受体（EGFR）突变：与吉非替尼治疗临床反应的相关性
Science. 2004 Jun 4;304(5676):1497-500. doi: 10.1126/science.1099314. Epub 2004 Apr 29.
6
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.表皮生长因子受体中的激活突变是非小细胞肺癌对吉非替尼产生反应的基础。
N Engl J Med. 2004 May 20;350(21):2129-39. doi: 10.1056/NEJMoa040938. Epub 2004 Apr 29.
Zotero 插件